We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+10.43%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$260M
AUM Growth
+$45.7M
Cap. Flow
+$28M
Cap. Flow %
10.77%
Top 10 Hldgs %
28.77%
Holding
76
New
17
Increased
25
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$6.57M
2
MRK icon
Merck
MRK
+$6.28M
3
AZN icon
AstraZeneca
AZN
+$5.4M
4
COR icon
Cencora
COR
+$5.05M
5
CI icon
Cigna
CI
+$4.33M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.1M
2
UHS icon
Universal Health Services
UHS
+$6.51M
3
CAH icon
Cardinal Health
CAH
+$5.01M
4
SNN icon
Smith & Nephew
SNN
+$3.81M
5
UNH icon
UnitedHealth
UNH
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 93.84%
2 Energy 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$69.5B
$8.5M 3.27%
260,000
+85,000
+49% +$2.56M
SYK icon
2
Stryker
SYK
$125B
$8.44M 3.25%
50,000
+15,000
+43% +$2.52M
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
$7.53M 2.9%
30,586
+8,619
+39% +$1.88M
BMY icon
4
Bristol-Myers Squibb
BMY
$133B
$7.47M 2.87%
135,000
+55,000
+69% +$2.97M
HUM icon
5
Humana
HUM
$43.7B
$7.44M 2.86%
25,000
-5,000
-17% -$1.46M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$121B
$7.41M 2.85%
43,600
+8,600
+25% +$1.33M
MOH icon
7
Molina Healthcare
MOH
$10.2B
$7.35M 2.82%
75,000
-5,000
-6% -$436K
TEVA icon
8
Teva Pharmaceuticals
TEVA
$40.8B
$6.93M 2.67%
285,000
-70,000
-20% -$1.43M
CNC icon
9
Centene
CNC
$30.7B
$6.91M 2.66%
112,200
-16,048
-13% -$925K
LLY icon
10
Eli Lilly
LLY
$1.02T
$6.83M 2.62%
+80,000
New +$6.57M
COR icon
11
Cencora
COR
$60.6B
$6.82M 2.62%
80,000
+57,500
+256% +$5.05M
BIIB icon
12
Biogen
BIIB
$30B
$6.53M 2.51%
22,500
+7,500
+50% +$2.11M
MRK icon
13
Merck
MRK
$322B
$6.45M 2.48%
+111,336
New +$6.28M
TMO icon
14
Thermo Fisher Scientific
TMO
$213B
$6.21M 2.39%
30,000
+10,000
+50% +$2.12M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.6B
$6.12M 2.35%
65,000
+45,000
+225% +$3.94M
ISRG icon
16
Intuitive Surgical
ISRG
$127B
$5.98M 2.3%
37,500
– –
ELV icon
17
Elevance Health
ELV
$81.5B
$5.95M 2.29%
25,000
+5,000
+25% +$1.16M
BAX icon
18
Baxter International
BAX
$13.5B
$5.91M 2.27%
80,000
-20,000
-20% -$1.41M
ABT icon
19
Abbott
ABT
$183B
$5.79M 2.23%
95,000
-40,000
-30% -$2.43M
VTRS icon
20
Viatris
VTRS
$20.4B
$5.78M 2.22%
160,000
– –
INCY icon
21
Incyte
INCY
$24.2B
$5.7M 2.19%
85,000
+40,000
+89% +$2.74M
AZN icon
22
AstraZeneca
AZN
$263B
$5.27M 2.03%
+75,000
New +$5.4M
BIO icon
23
Bio-Rad Laboratories Class A
BIO
$8.71B
$5.05M 1.94%
17,500
+2,500
+17% +$690K
UNH icon
24
UnitedHealth
UNH
$376B
$5.05M 1.94%
20,573
-14,427
-41% -$3.46M
ZTS icon
25
Zoetis
ZTS
$32.4B
$4.68M 1.8%
55,000
+15,000
+38% +$1.27M
1
2 3

Similar funds

RSF
Rik Saylor Financial Fairfield, Ohio $132M AUM 16.04% 1-Year Est. Return
VF
Visa Foundation San Francisco, California $132M AUM 14.62% 1-Year Est. Return
AFP
ATX Financial Planning Austin, Texas $132M AUM
GCM
Graver Capital Management Columbus, Ohio $132M AUM 16.79% 1-Year Est. Return
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
GCM
Gunpowder Capital Management Towson, Maryland $132M AUM
FF
Fairway Financial Casselberry, Florida $132M AUM 13.23% 1-Year Est. Return
PF
PlanVest Financial Gaithersburg, Maryland $131M AUM

Sivik Global Healthcare's Q2 2018 Portfolio in Review

As of Q2 2018, Sivik Global Healthcare held 76 positions worth $260M, up 21% from $214M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Sivik Global Healthcare deployed $28M of net new capital in Q2 2018, opening 17 new positions and adding to 25 existing holdings. Its largest new stake was Eli Lilly: 80,000 shares worth $6.83M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.46M trimmed.

  • Sivik Global Healthcare's largest Q2 2018 buy was Eli Lilly: 80,000 shares worth $6.83M.
  • Sivik Global Healthcare added most to Cencora in Q2 2018, an estimated $5.05M increase.
  • Sivik Global Healthcare's biggest Q2 2018 reduction was UnitedHealth, cutting an estimated $3.46M.
  • Sivik Global Healthcare fully exited AbbVie in Q2 2018, selling an estimated $7.1M.
  • Sivik Global Healthcare's ten largest holdings make up 29% of its $260M portfolio in Q2 2018.
  • Sivik Global Healthcare opened 17 new positions and closed 15 in Q2 2018.
  • Sivik Global Healthcare's portfolio value rose 21% quarter-over-quarter to $260M.

Based on Sivik Global Healthcare's 13F filing for Q2 2018, filed 6 Aug 2018.